Coagulation factor xa (recombinant), inactivated-zhzo - Biologic Drug Details

Summary for coagulation factor xa (recombinant), inactivated-zhzo

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for coagulation factor xa (recombinant), inactivated-zhzo Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for coagulation factor xa (recombinant), inactivated-zhzo Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for coagulation factor xa (recombinant), inactivated-zhzo Derived from Patent Text Search

No patents found based on company disclosures

Coagulation factor xa (recombinant), inactivated-zhzo Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Coagulation Factor Xa (Recombinant), Inactivated-zhzo (ANDEXXA)

Introduction

ANDEXXA, or coagulation factor Xa (recombinant), inactivated-zhzo, is a groundbreaking biologic drug designed to reverse the anticoagulant effects of rivaroxaban and apixaban in patients experiencing life-threatening or uncontrolled bleeding. This article delves into the market dynamics and financial trajectory of ANDEXXA, highlighting its unique position, regulatory approvals, market demand, and financial performance.

Regulatory Approval and Indication

ANDEXXA received accelerated approval from the FDA in 2018 for its indication in reversing anticoagulation in patients treated with rivaroxaban or apixaban due to life-threatening or uncontrolled bleeding[3][4][5].

Accelerated Approval

The approval was based on the change from baseline in anti-factor Xa (FXa) activity in healthy volunteers, although an improvement in hemostasis has not been established. Continued approval is contingent upon the results of studies demonstrating an improvement in hemostasis in patients[1][4].

Mechanism of Action

ANDEXXA exerts its procoagulant effect by binding and sequestering the FXa inhibitors rivaroxaban and apixaban. Additionally, it inhibits the activity of Tissue Factor Pathway Inhibitor (TFPI), which can increase tissue factor-initiated thrombin generation[2][4].

Market Demand

The demand for ANDEXXA is driven by the increasing use of direct oral anticoagulants (DOACs) like rivaroxaban and apixaban. These medications are widely prescribed for conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. However, the lack of a specific reversal agent for these DOACs until ANDEXXA's approval created a significant clinical need.

Clinical Need

The introduction of ANDEXXA addresses this need by providing a rapid and effective way to reverse anticoagulation in emergency situations, thereby reducing the risk of severe bleeding complications.

Market Competition

ANDEXXA is the first and, to date, the only FDA-approved recombinant FXa product specifically indicated for the reversal of rivaroxaban and apixaban. This unique positioning gives ANDEXXA a significant market advantage.

Competitive Landscape

While other reversal agents exist for different types of anticoagulants (e.g., idarucizumab for dabigatran), ANDEXXA's specificity for FXa inhibitors sets it apart in the market. This lack of direct competition enhances its market share and revenue potential.

Financial Performance

Since its approval, ANDEXXA has shown promising financial performance, driven by its critical role in emergency medicine.

Revenue Growth

The revenue for ANDEXXA has been increasing steadily, reflecting the growing adoption of the drug in clinical settings. The unique indication and lack of competition contribute significantly to its revenue growth.

Cost and Pricing

ANDEXXA is a high-value biologic, and its pricing reflects its complex manufacturing process and the critical nature of its use. The cost of treatment can be substantial, but it is often justified by the life-saving benefits it provides.

Clinical Trials and Ongoing Research

The ongoing Phase 3b/4 studies aim to evaluate ANDEXXA’s clinical benefit versus the available standard of care. These studies are crucial for establishing long-term efficacy and safety data, which can further solidify ANDEXXA's market position[4].

Safety and Efficacy Concerns

While ANDEXXA has shown efficacy in reversing anti-FXa activity, there are concerns regarding its safety profile. The drug has been associated with thromboembolic events, and patients must be monitored closely for these risks[2].

Monitoring and Treatment

Healthcare providers must balance the benefits of ANDEXXA against the potential risks, ensuring that patients are closely monitored for symptoms and signs that precede cardiac arrest or other thromboembolic events.

Market Expansion and Global Reach

ANDEXXA is manufactured by AstraZeneca AB and has been approved in several countries. The global reach of the drug is expanding, driven by the increasing recognition of its clinical value.

International Approvals

Regulatory approvals in various regions have facilitated the global distribution of ANDEXXA, making it accessible to a broader patient population.

Key Takeaways

• Unique Indication: ANDEXXA is the first and only FDA-approved drug for reversing the anticoagulant effects of rivaroxaban and apixaban.
• Market Demand: Driven by the increasing use of DOACs and the clinical need for a reversal agent.
• Financial Performance: Steady revenue growth due to its critical role in emergency medicine.
• Safety and Efficacy: Ongoing studies to establish long-term efficacy and safety data.
• Global Reach: Expanding international approvals and distribution.

FAQs

What is ANDEXXA used for?

ANDEXXA is used to treat life-threatening or uncontrolled bleeding in patients who are receiving rivaroxaban or apixaban.

How does ANDEXXA work?

ANDEXXA works by binding and sequestering the FXa inhibitors rivaroxaban and apixaban, and by inhibiting the activity of Tissue Factor Pathway Inhibitor (TFPI).

What are the potential risks associated with ANDEXXA?

ANDEXXA is associated with thromboembolic events, and patients must be monitored closely for these risks.

Is ANDEXXA approved globally?

ANDEXXA has been approved in several countries, and its global reach is expanding.

What is the current status of ongoing research for ANDEXXA?

Ongoing Phase 3b/4 studies are evaluating ANDEXXA’s clinical benefit versus the available standard of care to establish long-term efficacy and safety data.

Sources

1. ANDEXXA.com: Anticoagulation Reversal Agent | ANDEXXA | For HCPs
2. FDA: Package Insert - ANDEXXA
3. FDA: ANDEXXA - FDA
4. FDA: May 3, 2018 Summary Basis for Regulatory Action - ANDEXXA
5. Mayo Clinic: Coagulation factor xa recombinant, inactivated-zhzo (intravenous route)